NRGene, an agricultural genomics company based in Israel, and Kayagene, a California-based cannabis breeding company, have announced the completion of the first fully-phased cannabis genome using NRGene’s DeNovoMAGIC technology.
NRGene has created a full suite of tools to help breeders achieve commercial targets. By using these genomic tools, master growers are now able to make selections earlier in the breeding program, dramatically accelerating a process that usually takes years to develop and comes with substantial operating costs.
“Advanced genomics give companies like Kayagene the advantage of having a robust program that can utilize time and money more effectively. When you’re working with something so critical to your breeding program, it’s important to work with the leaders in the space” said Dr. Christopher E. Hohn, Director of R&D, Kayagene. ”I see NRGene advancing cannabis genomics and breeding over the next couple of years in great ways.”
“We have now only begun to realize the potential in cannabis, as over 99% of its genetic diversity was never studied,” said Dr. Gil Ronen, President, NRGene. “Our fully-phased genomes reveal the hidden secrets of diverse cannabis strains and enable us to efficiently implement them for future treatments of multiple human medical conditions.”
For more information:
www.nrgene.com/solutions/cannabis
